Financials in USD. Standardized financial statements.
A compact view of how Appili Therapeutics Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $100,443 | $827,407 | $334,177 | $1.39M | $0 | $199,106 | $0 | $0 | $0 |
| Revenue Growth? | -87.9% | +147.6% | -76.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $14,836 | $0 | $20,714 | $17,670 | $10,505 |
| Gross Profit? | $100,443 | $827,407 | $334,177 | $1.39M | -$14,836 | $199,106 | -$20,714 | -$17,670 | -$10,505 |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | 0.0% | +100.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $291,282 | $2.99M | $8.11M | $25.01M | $16.28M | $4.37M | $7.14M | $3.77M | $3.76M |
| Operating Income? | -$190,839 | -$2.16M | -$7.78M | -$23.62M | -$16.30M | -$4.37M | -$7.16M | -$3.77M | -$3.77M |
| EBITDA? | $360,566 | -$2.07M | -$8.10M | -$23.51M | -$15.65M | -$5.39M | -$6.52M | -$6.54M | -$3.22M |
| Income Before Tax | -$2.61M | -$3.71M | -$9.21M | -$25.08M | -$14.95M | -$4.33M | -$4.95M | -$3.98M | -$2.30M |
| Income Tax Expense | $18,830 | $69,583 | $36,392 | $38,459 | -$627,892 | -$243,427 | -$621,608 | -$46,180 | -$541,511 |
| Net Income? | -$2.62M | -$3.78M | -$9.24M | -$25.12M | -$14.33M | -$4.33M | -$4.33M | -$3.98M | -$1.75M |
| EPS? | $-0.02 | $-0.03 | $-0.08 | $-0.38 | $-0.24 | $-0.13 | $-0.14 | $-0.12 | $-0.06 |
| Diluted EPS? | $-0.02 | $-0.03 | $-0.08 | $-0.38 | $-0.24 | $-0.13 | $-0.14 | $-0.12 | $-0.06 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality